AI-based “Cerviray” confirmed for supply to about 100 OB-GYN clinics in Indonesia by year-end
AIDOT (CEO Jeong Jae-hoon) announced on the 12th that its AI-based cervical cancer interpretation system, “Cerviray A.I.”, has been officially registered with Indonesia’s procurement agency.
In April of this year, AIDOT completed official regulatory approval with Indonesia’s MOH (Ministry of Health) and successfully achieved local commercialization. With this additional official registration with the Indonesian procurement agency, the company expects to gain further momentum in expanding the local market.
A representative from Pyridam Farma, AIDOT’s local partner, said, “After examining cervical cancer screening and diagnostic methods in Indonesia, we found that HPV testing and cytology have many aspects that do not fit Indonesia’s reality. Various issues also occurred, such as problems during equipment adoption, low hospital accessibility, and shortages of medical personnel,” adding, “For these reasons, we confirmed that Cerviray, an AI-based VIA method, is the optimal cervical cancer screening approach.”
In particular, AIDOT visited Indonesia starting on the 8th and successfully completed training and seminars on Cerviray at major tertiary general hospitals. The company also decided to supply Cerviray to approximately 100 hospitals—centered around key hub hospitals in Indonesia—by the end of this year.
With Cerviray now officially registered as a medical device with Indonesia’s procurement agency, AIDOT will be able to further pursue expanded supply through public procurement channels.
Im Ga-ram, team leader in AIDOT’s Global Sales & Marketing Team, who oversaw the local training, said, “Through this training, Pyridam Farma was able to better understand Cerviray, and we were also able to strengthen the partnership,” adding, “Based on this, active sales efforts will unfold in the Indonesian market.”
She added, “Through this local training, we will contribute both to eradicating cervical cancer among Indonesian women and to AIDOT’s expansion into the global market.”
Published: August 12, 2022 / The Medical News / Reporter Kim Hyun-gi
